News

A team of researchers at the University of Kentucky has found that a drug used to treat multiple sclerosis (MS) is potentially effective as a therapy for Alzheimer’s disease.

Labor Day, September 4, WKYT-TV, is highlighting the world-class work going on at the University of Kentucky’s Sanders-Brown Center on Aging. The Lexington-based CBS affiliate will air a 30-minute special on their second station, The CW, at 6:30 p.m.

A recent study from the lab of the Sanders-Brown Center on Aging Director Linda Van Eldik, Ph.D., centers around the idea that various anti-inflammatory drugs could be effective treatments for Alzheimer’s disease.

The U.S. Food and Drug Administration (FDA) granted full approval to lecanemab, marketed as Leqembi, for the treatment of Alzheimer’s disease. The University of Kentucky’s Sanders-Brown Center on Aging has been working with this drug and others like it for more than a decade.

Throughout March, UK is spotlighting Women Making History. These women are leading their fields of research and impacting the lives of Kentuckians. For Allison Gibson, Ph.D., her passion is helping some of the most vulnerable Kentuckians.

The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of a promising drug known as lecanemab.

The Pat Summitt Foundation presented a $25,000 grant to the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) during the UK women’s basketball game against Auburn University on January 26, 2023.

Sanders-Brown Center on Aging is now a site for the first-ever clinical trial testing the effect lecanemab has in people with no cognitive symptoms of Alzheimer’s disease but have amyloid present in their brains.

Donna Wilcock, Ph.D., was awarded a $1.7 million National Institutes of Health grant for her lab’s exploration of adverse effects of two new Alzheimer’s disease drugs shown to slow the progression of cognitive decline.

The focus of the work done by Elizabeth Rhodus, Ph.D., is to enhance sensory input in order to improve behavioral symptoms in people with Alzheimer's disease and related dementias.